CTOs on the Move

Austills Rehabilitation Services

www.austills.com

 
Austill's specializes in providing pediatric therapy services to School Districts, Early Intervention Programs, and County-Wide Regional Special Education providers. Since 1984, Austill's has provided therapy for educational programs. We customize all
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.austills.com
  • 100 John Robert Thomas Dr
    Exton, PA USA 19341
  • Phone: 610.363.7009

Executives

Name Title Contact Details

Similar Companies

Medical Management Strategies

Medical Management Strategies is a San Luis Obispo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alzheirmer's Association

Alzheirmer's Association is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tomah Health

At Tomah Health, we are inspiring health, wellness and balance for patients, families and our community, together in care. We have been caring for our community since 1952 and Tomah Health advances excellence in care by providing quality, compassionate healthcare close to home. We are growing for you and our community to continue to provide superior healthcare for generations to come.

Sequel Systems

Sequel Systems is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.